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1. INTRODUCTION {#cas14315-sec-0001}
===============

Intrahepatic cholangiocarcinoma (ICC), arising from the epithelial cells of segmental or proximal branches of the bile duct, accounts for 5%‐30% of all primary liver malignancies.[1](#cas14315-bib-0001){ref-type="ref"} The incidence and mortality rates of ICC have increased globally over the past 30 years, indicating that ICC has become a growing clinical problem.[2](#cas14315-bib-0002){ref-type="ref"}, [3](#cas14315-bib-0003){ref-type="ref"} Surgical resection is the mainstay of curative treatment and is associated with improved survival in selected ICC patients.

Tumor‐infiltrating lymphocytes have been shown to be a determinant of carcinogenesis and progression, and may also serve as a predictor of patient response to neoadjuvant chemotherapy.[4](#cas14315-bib-0004){ref-type="ref"}, [5](#cas14315-bib-0005){ref-type="ref"} Wang et al[6](#cas14315-bib-0006){ref-type="ref"} reported that IL‐17A^+^ immune cell infiltration was correlated with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. In addition, Nywening et al[7](#cas14315-bib-0007){ref-type="ref"} revealed that dual targeting of tumor‐associated CCR2^+^ macrophages and CXCR2^+^ neutrophils could improve chemotherapeutic responses and enhance antitumor immunity by disrupting myeloid recruitment in pancreatic ductal adenocarcinoma. In colorectal cancer, CD8^+^ and CD45RO^+^ lymphocytes were found to be prognostic factors that might play a critical role in controlling tumor progression,[8](#cas14315-bib-0008){ref-type="ref"} and were defined as a new component in the classification criteria of colorectal cancer.[9](#cas14315-bib-0009){ref-type="ref"} Previously, we observed that intratumoral IL‐17^+^ and CD66b^+^ immune cells were independent prognostic factors for long‐term survival of ICC patients.[10](#cas14315-bib-0010){ref-type="ref"} In addition, an elevated neutrophil/lymphocyte ratio (≥3) was able to predict worse survival for surgically resected ICC patients, including in patients that received neoadjuvant chemotherapy.[11](#cas14315-bib-0011){ref-type="ref"} These results suggested that identification of robust prognostic factors may enhance the predictive power of the current staging systems for ICC patients. However, the nature of immune infiltration in ICC remains to be comprehensively explored.

In this study, we first investigated the immune microenvironment of ICC based on gene expression profiles from a public database. Then, we examined the histopathological expression levels of 16 immune markers in ICC tissue specimens. By using the least absolute shrinkage and selection operator (LASSO) Cox method on the basis of overall survival (OS), we developed an immune signature for ICC patients (IS~ICC~) based on 5 prognostic immune features, and integrated the clinicopathological characteristics and IS~ICC~ into a new prognostic model. Finally, we compared the performance of this model with three existing staging systems.

2. MATERIALS AND METHODS {#cas14315-sec-0002}
========================

2.1. Patients {#cas14315-sec-0003}
-------------

A retrospective study was carried out on a primary dataset of patients who received hepatic resection for ICC between February 2005 and July 2011 at the Department of Liver Surgery, Zhongshan Hospital. Standard liver resection techniques were applied.[12](#cas14315-bib-0012){ref-type="ref"} Tumor stage was determined according to the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control TNM classification system. Tumor differentiation was graded according to the Edmonson‐Steiner criteria.[13](#cas14315-bib-0013){ref-type="ref"} Patients were confirmed to have ICC with histopathological evidence before study enrollment, with no history of other cancers, with Child‐Pugh class A, and with no history of anticancer therapy before surgery; all these patients underwent complete resection of tumors, and showed no signs of distant or intrahepatic metastasis. A total of 280 patients were enrolled. Data were censored at the last follow up for patients without recurrence or death. OS and recurrence‐free survival (RFS) was defined as the interval between the date of surgery to the date of death or recurrence. The study was approved by the institutional review board of Zhongshan Hospital and was conducted in accordance with the standards of the Declaration of Helsinki. Informed consent was obtained from each patient prior to treatment.

Patients were randomly assigned to the derivation cohort (n = 168) or the validation cohort (n = 112) (Figure [S1](#cas14315-sup-0001){ref-type="supplementary-material"}). As summarized in Table [1](#cas14315-tbl-0001){ref-type="table"}, no significant differences were observed in the clinicopathological characteristics of ICC between the two cohorts. HBsAg‐positive patients accounted for 39.9% of individuals in the derivation cohort and 45.5% in the validation cohort, respectively. The median levels of AFP, CEA and CA19‐9 were 2.7 ng/mL, 2.5 μg/mL and 37.7 U/mL in the derivation cohort, respectively. During the follow‐up period, 71.4% of all patients (200/280) developed recurrence and 62.5% (175/280) died. For the entire cohort, the median follow‐up time was 44.5 months (range, 7.3‐109.5 months), the median OS was 28.3 months (95% CI, 20.8‐35.8 months), and the 1, 3 and 5‐year OS rates were 73.4%, 44.4% and 32.4%, respectively.

###### 

Demographic, clinical and tumor characteristics of patients with intrahepatic cholangiocarcinoma

  Patient demographics                                             Derivation cohort (n = 168)   Validation cohort (n = 112)   *P*‐value
  ---------------------------------------------------------------- ----------------------------- ----------------------------- -----------
  Age, year                                                                                                                    
  \<60 years                                                       86 (51.2%)                    67 (59.8%)                    .19
  ≥60 years                                                        82 (48.8%)                    45 (40.2%)                     
  Sex (male), n (%)                                                99 (58.9%)                    74 (66.1%)                    .28
  Etiology                                                                                                                     
  HBV                                                              67 (39.9%)                    51 (45.5%)                    .57
  HCV                                                              3 (2.8%)                      1 (0.9%)                       
  Others                                                           98 (58.3%)                    60 (53.6%)                     
  AFP, ng/mL                                                       2.7 (1.9, 4.8)                2.7 (2.0, 4.7)                .51
  CEA, μg/mL                                                       2.5 (1.4, 4.1)                2.2 (1.4, 4.5)                .67
  CA19‐9, U/mL                                                     37.7 (16.0, 283.2)            37.3 (15.7, 178.6)            .63
  Albumin, g/L                                                     43.0 (40.0, 45.0)             43.0 (40.0, 46.0)             .55
  Bilirubin, μmol/L                                                11.8 (8.8, 15.3)              11.8 (9.3, 16.3)              .62
  ALT, IU/L                                                        20.5 (13.8, 35.3)             21.0 (15.0, 36.5)             .60
  GGT, U/L                                                         48.0 (31.0, 100.3)            46.55 (31.8, 92.0)            .51
  Platelets, 10^3^/μL                                              176.5 (133.8, 217.3)          190.5 (152.0, 216.3)          .20
  Tumor nodularities, n (%)                                                                                                    
  1                                                                134 (79.8%)                   96 (85.7%)                    .44
  2                                                                20 (11.9%)                    9 (8.0%)                       
  ≥3                                                               14 (8.3%)                     7 (6.3%)                       
  Tumor diameter, cm                                               6.0 (4.4, 8.0)                6.0 (4.4, 9.0)                .96
  Tumor differentiation, n (%)                                                                                                 
  I‐II                                                             117 (69.6%)                   74 (66.1%)                    .62
  III‐IV                                                           51 (30.4%)                    38 (33.9%)                     
  Vascular invasion (yes), n (%)                                   7 (4.2%)                      7 (6.3%)                      .61
  Lymphoid metastasis (yes), n (%)                                 9 (5.4%)                      8 (7.1%)                      .72
  Direct invasion and local extrahepatic metastasis (yes), n (%)   2 (1.2%)                      0 (0%)                        .52
  Occlusion, min                                                                                                               
  \<15 min                                                         114 (67.9%)                   67 (59.8%)                    .21
  ≥15 min                                                          54 (32.1%)                    45 (40.2%)                     

Values are presented as patient number (%) or median (Q1, Q3).

Abbreviations: AFP, α‐fetoprotein; ALT, alanine aminotransferase; CA19‐9, carbohydrate 19‐9; CEA, carcino‐embryonic antigen; GGT, γ‐glutamyl transpeptidase; HBV, hepatitis B virus; HCV, hepatitis C virus; VI, vascular invasion.
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2.2. Tissue microarray construction and immunohistochemistry {#cas14315-sec-0004}
------------------------------------------------------------

Tissue microarray (TMA) construction was performed as previously described.[14](#cas14315-bib-0014){ref-type="ref"}, [15](#cas14315-bib-0015){ref-type="ref"} Briefly, two representative areas with infiltrating lymphocytes were selected on H&E‐stained slides. Duplicate cores (2 μm in diameter) were taken, arrayed and re--embedded from tumor and peritumor regions. Fourteen monoclonal and two polyclonal antibodies against CD3, CD4, CD8, CD14, CD20, CD27, CD45RO, CD45RA, CD57, CD66b, CD68, CD103, Foxp3, CXCR5, PD‐L1 and PD1 were used for staining, as reported previously.[15](#cas14315-bib-0015){ref-type="ref"} To evaluate peritumoral and intratumoral infiltrating immune cells, the three most representative and independent fields were selected and photographed at ×200 magnification. Identical settings were used for each photograph. The numbers of positive cells were counted and recorded using a computer‐automated method (Image‐Pro Plus 6.0, Media Cybernetics) as previously described.[15](#cas14315-bib-0015){ref-type="ref"}, [16](#cas14315-bib-0016){ref-type="ref"} Figure [S2](#cas14315-sup-0001){ref-type="supplementary-material"} presents the spot and the captured spot (×200) with image software. The mean value of positive cells was used for statistical analysis. More detailed information is presented in the Supplementary Methods and Table [S1](#cas14315-sup-0001){ref-type="supplementary-material"}.

2.3. Establishment of an immune signature for intrahepatic cholangiocarcinoma (IS~ICC~) patients {#cas14315-sec-0005}
------------------------------------------------------------------------------------------------

The least absolute shrinkage and selection operator (LASSO) method, which is suitable for the analysis of high‐dimensional data, was used to select the most predictive immune features from the derivation cohort on the basis of OS and then construct a multi‐immune feature model.[17](#cas14315-bib-0017){ref-type="ref"} The "glment" package was used to perform LASSO Cox regression analysis.

2.4. Construction of IS~ICC~‐applied prediction model {#cas14315-sec-0006}
-----------------------------------------------------

For the model to achieve satisfactory performance, all the variables with *P* \< .1 in the univariate analysis were identified through a backward stepwise selection process based on the Akaike information criterion (AIC).[18](#cas14315-bib-0018){ref-type="ref"} The final prognostic model was determined on the basis of the lowest AIC instead of the variables (*P* \< .05) selected in the multivariate analysis. The IS~ICC~‐applied prediction model was calculated for each patient based on IS~ICC~ and clinical parameters.

2.5. Statistical analysis {#cas14315-sec-0007}
-------------------------

Statistical analyses were conducted with R version 3.1.0 (R Foundation, Vienna, Austria). Demographic and clinicopathological characteristics were presented as percentages or median values. Categorical variables were analyzed using Pearson's χ^2^ test or Fisher's exact test. The Wilcoxon test or Student's *t* test was used to evaluate continuous variables. OS curves were plotted using the Kaplan‐Meier method and compared using the log‐rank test. The performance of three staging systems and the IS~ICC~‐applied prediction model were compared with the rcorrp.cens package in Hmisc[19](#cas14315-bib-0019){ref-type="ref"} and validated in the validation cohort. According to the highest χ^2^‐value defined by Kaplan‐Meier survival analysis and log‐rank tests, ICC patients were categorized into three subgroups with X‐tile software version 3.6.1 (Yale University School of Medicine, New Haven, CT, USA).[20](#cas14315-bib-0020){ref-type="ref"} To investigate the performance of stratified IPM and three traditional staging systems, we chose the corrected AIC (AICc)[21](#cas14315-bib-0021){ref-type="ref"} to evaluate the correlation of the staging systems with patient survival and Wald χ^2^ tests to determine homogeneity.[22](#cas14315-bib-0022){ref-type="ref"} A *P*‐value \< .05 was considered statistically significant.

3. RESULTS {#cas14315-sec-0008}
==========

3.1. Characterization of the immune microenvironment of ntrahepatic cholangiocarcinoma {#cas14315-sec-0009}
--------------------------------------------------------------------------------------

To investigate the characteristics of immune microenvironment, a public dataset (GSE76297) of 91 ICC patients was obtained from the Gene Expression Omnibus of our study.[23](#cas14315-bib-0023){ref-type="ref"} By using the CIBERSORT‐inferred relative fractions of different immune cell types, we observed depletion of intratumoral plasma cells, CD8^+^ T cells, nature killer (NK) cells and monocytes, along with significant enrichment of T follicular helper (Tfh) cells, macrophage cells and dendritic cells (Figure [1](#cas14315-fig-0001){ref-type="fig"}A). Evaluation of the infiltrating immune cells using immunohistochemistry revealed similar results, with a decrease of CD4^+^, CD8^+^, CD20^+^ and CD27^+^ lymphocytes and an increase of Foxp3^+^, CXCT5^+^ and CD103^+^ lymphocytes. These results suggested an immune‐suppressive intratumoral immune microenvironment with loss of effector immune cells and accumulation of suppressive immune cells.

![Characterization of immune microenvironment and selection of immune features by using least absolute shrinkage and selection operator (LASSO) Cox analysis in intrahepatic cholangiocarcinoma (ICC) patients. A, Comparison of immune cells between tumor and adjacent non--tumor tissues in the GSE76297 dataset (upper panel) and 280 ICC specimens (lower panel). B, Correlation matrix followed by unsupervised hierarchical clustering in GSE76297 dataset (left) and 280 ICC specimens (right). C, The immune network of immune infiltrations in GSE76297 (left) and 280 ICC specimens (right). D, Five immune features selected using LASSO Cox regression analysis. Left panel: The two dotted vertical lines were drawn at the optimal scores by minimum criteria and 1‐s.e. criteria. Right panel: LASSO coefficient profiles of the 32 features. E, Expressions of selected prognostic features in ICC, including CD3~P~, CD45RA~P~, CD57~P~, PD‐L1~P~ and CD66b~T~ in 3 different patients. Bar, 20 μm. F, IS~ICC~ distribution of the 5 prognostic features in the derivation dataset and the validation dataset. Upper panel: IS~ICC~ distribution and patient survival status. Lower panel: heatmap presenting density of the 5 features in ICC patients](CAS-111-1084-g001){#cas14315-fig-0001}

Correlation analysis was conducted to investigate the correlations of immune cells in the GSE76297 dataset. Three clusters were identified in ICC tissues, characterized by markers of exhausted immune response (neutrophils and eosinophils), adaptive T response (plasma and NK cells) or both (CD8, Tregs and monocytes) (Figure [1](#cas14315-fig-0001){ref-type="fig"}B left). To confirm these results, the density of 16 immune infiltrations was examined using ICC TMA (Figure [S3](#cas14315-sup-0001){ref-type="supplementary-material"}). Figure [1](#cas14315-fig-0001){ref-type="fig"}B (right), which revealed three dominant clusters characterized by adaptive T response (CXCR5, CD20 and CD45RA; CD3, CD4, CD8, CD27 and CD45RO) or exhausted immune response (CD20, CD27 and CD45RA).

In the T cell network, the local coordination underlines the existence of tumor‐microenvironment compartments with different compositions that might influence the mobility and activity of T and B cells along with tumor progression.[24](#cas14315-bib-0024){ref-type="ref"} We constructed immune networks to evaluate the interactions of immune components in GSE76207 and 280 samples of ICC tissues. Figure [1](#cas14315-fig-0001){ref-type="fig"}C (left) reveals 2 independent networks with similar subnetworks of T cells (CD4, CD8, NK and Tregs). Interestingly, it was observed that CD4 might work as an important hub connecting adaptive T responses (NK, CD8 and Tregs) and exhausting immune response (plasma cells, monocytes or neutrophils) within peritumoral and intratumoral tissues. The network of immune features in 280 ICC tissue samples presented a similar pattern of separation between tumor and peritumor regions, while it was revealed that CD103^+^ cells may function as a connection between the two immune networks (Figure [1](#cas14315-fig-0001){ref-type="fig"}C right). We observed a similar coordination of CD4^+^ cells in histological evidence‐based immune populations, which was consistent with the results of GSE76297.

3.2. Establishment of IS~ICC~ {#cas14315-sec-0010}
-----------------------------

Using the LASSO Cox method, 5 out of 32 prognostic immune features were identified as having the highest predictive values on the basis of OS, including CD3~peritumor\ (p)~, CD57~P~, CD45RA~P~, CD66b~intratumor\ (T)~ and PD‐L1~P~ (Figure [1](#cas14315-fig-0001){ref-type="fig"}D). The expression pattern of 5 selected immune features is presented in Figure [1](#cas14315-fig-0001){ref-type="fig"}E. We applied a novel equation to each patient based on their levels of these specific factors (Figure [1](#cas14315-fig-0001){ref-type="fig"}F): the IS~ICC~ = (the level of CD45RA~P~ × 10.602 − the level of CD3~P~ × 6.025 − the level of CD57~P~ × 31.013 + the level of CD66b~T~ × 5.421 − the level of PD‐L1~P~ × 3.252) × 10^−4^. In this formula, the expression levels of the corresponding immune features refer to the numbers of positively stained cells in tumor or non--tumor tissues in the histological analysis.

3.3. Selection of prognostic factors {#cas14315-sec-0011}
------------------------------------

Eleven variables with *P* \< .1 were identified through univariate analysis (Table [2](#cas14315-tbl-0002){ref-type="table"}). Backward stepwise selection was performed using the lowest AIC and Cox proportional hazards regression modeling. Seven predictors were associated with the OS of patients with operable ICC, in which total bilirubin (95% CI, 1.000‐1.014, *P* = .046), tumor numbers (95% CI, 1.205‐4.289, *P* = .01) and IS~ICC~ (95% CI, 7.734‐131.243, *P* \< .001) were independent prognostic factors for OS of ICC patients, while CEA (95% CI, 1.998‐2.496, *P* = .05), CA19‐9 (95% CI, 0.981‐2.184, *P* = .06), GGT (95% CI, 0.901‐2.194, *P* = .13) and HBsAg (95% CI, 0.477‐1.082, *P* = .11) also tended to be associated with prognosis. Figure [2](#cas14315-fig-0002){ref-type="fig"}A indicates that the C‐index values of IS~ICC~ scores (derivation cohort, 0.673; validation cohort, 0.651) were better than those of selected prognostic predictors in both cohorts (derivation cohort, 0.513‐0.612; validation cohort, 0.498‐0.625).

###### 

Cox proportional hazards regression analysis of the association between variables and overall survival

  Variable                              Univariate analysis   Multiple analysis                                     
  ------------------------------------- --------------------- ------------------- -------- -------- --------------- --------
  HBsAg (yes/no)                        0.631                 0.427‐0.933         .02      0.718    0.477‐1.082     .11
  CEA (≥5/＜5, ng/mL)                   2.029                 1.305‐3.152         .002     1.578    1.998‐2.496     .05
  CA19‐9 (≥37/＜37, U/mL)               1.466                 1.003‐2.142         .048     1.464    0.981‐2.184     .06
  TB, μmol/L                            1.008                 1.001‐1.015         .03      1.007    1.000‐1.014     .046
  GGT (≥40/＜40, U/L)                   1.813                 1.194‐2.754         .005     1.406    0.901‐2.194     .13
  Tumor numbers                                                                                                     
  1 nodule                                                                                                           
  2 nodules                             1.153                 0.641‐1.263         .63      0.996    0.543‐1.826     .99
  ≥3 nodules                            2.275                 0.641‐1.263         .006     2.273    1.205‐4.289     .01
  IS~ICC~                               20.949                5.947‐73.796        \<.001   31.859   7.734‐131.243   \<.001
  Tumor diameter, cm                    1.067                 1.015‐1.122         .01                                
  Tumor differentiation (I‐II/III‐IV)   1.495                 1.010‐2.213         .045                               
  Lymphoid metastasis (yes/no)          2.14                  0.988‐4.636         .05                                
  Blood loss volume, mL                 1.001                 1.000‐1.001         .006                               

Abbreviations: CA19‐9, carbohydrate antigen 19‐9; CEA, carcino‐embryonic antigen; GGT, γ‐glutamyl transpeptidase; HBsAg, hepatitis B surface antigen; IS~ICC~, immune signature for ICC; TB, total bilirubin.
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![A, Receiver operating characteristic (ROC) curves for IS~ICC~ and six selected risk predictors in the derivation and validation cohorts. B, ROC curves for IS~ICC~‐applied prediction model and three traditional staging systems in the derivation cohort and the validation cohort](CAS-111-1084-g002){#cas14315-fig-0002}

3.4. Construction and performance of IS~ICC~‐applied prediction model {#cas14315-sec-0012}
---------------------------------------------------------------------

The 7 prognostic factors were integrated into an IS~ICC~‐applied prediction model, the formula of which was = 79.615 − 4.779 × the status of HBsAg + 0.101 × total bilirubin + 4.926 × the status of GGT + 5.504 × the status of CA19‐9 + 6.593 × the status of CEA + 10.946 × the status of lymphoid metastasis − 0.057 × the status of tumor numbers + 50 × IS~ICC~. Different values were assigned for calculation according to the status of these parameters: for HBsAg, a positive status was defined as 2, while a negative status was defined as 1; for the status of GGT, a GGT level \<40 U/L was defined as 0 and ≥40 U/L as 1; CEA level \<5 μg/mL was defined as 0, CEA level ≥5 μg/mL was equivalent to 1; CA19‐9 level \<37 μg/mL was defined as 0, while CA19‐9 ≥37 μg/mL was equivalent to 1; a positive lymphoid metastasis status was defined as 1 and negative as 0; and for tumor numbers, the presence of one tumor was defined as 1, two as 2 and \>2 as 3.

Compared to three traditional staging systems for ICC, the IS~ICC~‐applied prediction model provided better predictive efficacy for resectable ICC (Figure [2](#cas14315-fig-0002){ref-type="fig"}B). In the derivation cohort, the C‐index of the IS~ICC~‐applied prediction model was 0.719 (95% CI, 0.660‐0.777), which was higher than the C‐index values of AJCC 7th, Nathan and LCSGJ, which were 0.553 (95% CI, 0.506‐0.600), 0.552 (95%CI, 0.505‐0.559), and 0.558 (95% CI, 0.509‐0.606), respectively. Similarly, the C‐index of the IS~ICC~‐applied prediction model (0.667 \[95% CI, 0.581‐0.732\]) in the validation cohort was also higher than the C‐index values of the three traditional staging systems: AJCC 7th, 0.578 (95% CI, 0.522‐0.636); Nathan, 0.570 (95% CI, 0.514‐0.626); and LCSGJ, 0.577 (95% CI, 0.519‐0.635).

3.5. Stratifying risk of IS~ICC~‐applied prediction model in intrahepatic cholangiocarcinoma {#cas14315-sec-0013}
--------------------------------------------------------------------------------------------

The optimal cutoff scores of the IS~ICC~‐applied prediction model were determined using the X‐tile software,[20](#cas14315-bib-0020){ref-type="ref"} and the derivation cohort and the validation cohort were each categorized into three subgroups (score 1:0 to 78.3; score 2:78.3 to 87.7; score 3: more than 87.7) (Figure [S4](#cas14315-sup-0001){ref-type="supplementary-material"}). Kaplan‐Meier analysis indicated that both cohorts were well stratified (the derivation cohort: score 1 vs 2: *P* \< .001; score 2 vs 3: *P* \< .001; the validation cohort: score 1 vs 2: *P* = .008; score 2 vs 3: *P* = .04).

Furthermore, in this study, we used the corrected AIC values and homogeneity analysis to assess the prognostic efficacy of traditional staging systems and the IS~ICC~‐applied prediction model. In the derivation cohort, the stratification of the IS~ICC~‐applied prediction model showed the highest homogeneity (39.3) and the lowest AIC value (1017.5) (Table [3](#cas14315-tbl-0003){ref-type="table"}). A similar trend was observed in the validation cohort.

###### 

Comparison of prognostic performance among 3 staging systems and the stratified IS~ICC~‐applied prediction model in the derivation cohort and validation cohort

  Model                                         Derivation cohort   Validation cohort          
  --------------------------------------------- ------------------- ------------------- ------ -------
  Stratified IS~ICC~‐applied prediction model   39.3                1017.5              17.8   648.6
  AJCC 7th for ICC                              6.0                 1050.8              9.4    657.0
  Nathan                                        6.1                 1052.7              7.1    659.3
  LCSGJ                                         7.3                 1049.5              7.5    658.9

Abbreviations: AIC, Akaike information criteria; AJCC, American Joint Committee on Cancer; IS~ICC~, immune signature for ICC; LCSGJ, Liver Cancer Study Group of Japan.
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4. DISCUSSION {#cas14315-sec-0014}
=============

Immune cell infiltration is a common feature in various types of cancer,[25](#cas14315-bib-0025){ref-type="ref"} but the roles of lymphocytes in tumor progression and individualized survival prediction remain to be explored in ICC patients. In this study, we constructed an individualized immune signature and developed a novel immune prognostic score for ICC patients. The histological evidence‐based immune features enhanced the performance of survival prediction, suggesting that the novel clinical and IS~ICC~‐applied prediction model may be superior to the three existing staging systems for selected ICC (Figure [3](#cas14315-fig-0003){ref-type="fig"}).

![Kaplan‐Meier survival curves of the derivation cohort and the validation cohort categorized by different staging systems (stratified prediction model; AJCC 7th for ICC; LCSGJ; Nathan)](CAS-111-1084-g003){#cas14315-fig-0003}

To investigate the characteristics of the immune microenvironment, we analyzed the gene expression profiles from GEO to assess various immune components in neoplastic or adjacent non--neoplastic specimens using the CIBERSORT method. Reductions of plasma cells, Tfh, macrophages and NK cells were observed in neoplastic tissues of the GSE76297 dataset. Consistent with the results for GSE76297 and HCC,[26](#cas14315-bib-0026){ref-type="ref"} the intratumoral density of CD68^+^, CD57^+^, CD27^+^ and CD103^+^ cells was significantly lower than for the adjacent liver tissues, suggesting a generalized immunosuppressive status of ICC's intratumoral environment.

In the present study, four types of immune cells (CD3, CD45RA, CD57 and PD‐L1) were identified in adjacent non--tumor tissues, and one (CD66b) in neoplastic tissues. Inconsistent with previous studies on ICC[27](#cas14315-bib-0027){ref-type="ref"} or HCC,[28](#cas14315-bib-0028){ref-type="ref"} we observed that the density of peritumoral CD3^+^ cells was associated with patient survival. CD45RA (an immune marker of naïve T cells) exhibited reduced sensitivity to oxidative stress‐induced cell death while maintaining their suppressive function.[29](#cas14315-bib-0029){ref-type="ref"} Kenji et al reported that CD8^+^CD45RA^+^CD62L^+^CXCR3^+^CD73^+^ young memory T cells were associated with drug resistance.[30](#cas14315-bib-0030){ref-type="ref"} Growing evidence has revealed the negative correlation between high density of tumor‐infiltrating NK cells (CD57) and metastasis in gastrointestinal sarcoma patients.[31](#cas14315-bib-0031){ref-type="ref"} In our study, we found that peritumoral NK cells, rather than intratumoral NK cells, were associated with long‐term survival, implying that the immune status of peritumoral tissues may also influence the evasion and metastasis of tumor cells. Expression of PD‐L1 in tumor cells has been associated with improved response to anti--PD‐1/PD‐L1 inhibitors in patients with lung cancer.[32](#cas14315-bib-0032){ref-type="ref"} Notably, peritumoral PD‐L1^+^ immune cells were also identified in our study. Intratumoral neutrophils (CD66b) have been revealed to be a poor prognostic factor for various types of cancers;[10](#cas14315-bib-0010){ref-type="ref"}, [33](#cas14315-bib-0033){ref-type="ref"} we observed similar results in ICC patients. Unlike inflammation‐driven HCC, ICC is frequently accompanied by a dense desmoplastic stroma surrounding the malignant ducts and glands. The distinct carcinogenesis and biologic behaviors might be the reasons that 4 peritumoral immune features, out of 5 features, were correlated with patient survival in our study.

Of all tumor characteristics, tumor number was included in our final model. In accordance with previous study,[34](#cas14315-bib-0034){ref-type="ref"} the presence of multiple nodules was an independent factor that affected patient survival. In our previous studies,[35](#cas14315-bib-0035){ref-type="ref"}, [36](#cas14315-bib-0036){ref-type="ref"} CA19‐9 and CEA were identified as prognostic serum markers for liver cancer patients. Higher CA19‐9[36](#cas14315-bib-0036){ref-type="ref"} and CEA[34](#cas14315-bib-0034){ref-type="ref"} levels were associated with advanced TNM stages and poor prognosis in ICC patients. The status of liver function also influences patient survival. In this study, GGT was identified as one of the prognostic predictors. The IS~ICC~‐applied prediction model based on these clinical and immunological predictors demonstrated better performance in terms of patients' survival prediction.

A few limitations should be noted in our study. First, the prognostic model was established based on data from one single liver center in China. Second, only patients with resectable ICC were enrolled in this study, and the HBV‐related ICC accounted for 42.1% of the entire cohort. It remains to be explored whether our IS~ICC~‐applied prediction model is applicable to other patients. Third, further investigations are necessary to elucidate the underlying biologic mechanisms of the candidate markers, such as CD3, CD45RA, CD57, PD‐L1 and CD66b.

In conclusion, our histological evidence‐based prediction model was superior to current staging systems in predictive performance based on immune profile investigations and application of individualized immune signature. Further studies are needed to validate its predictive accuracy for prognosis and use for clinical application.
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